First-pass extracted concept

external cell-based cytokine factories

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Beyond CAR-T engineering, external cell-based 'cytokine factories' and immune-cytokines further underscore the versatility of localized cytokine delivery strategies.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1strategy promisesupports2025Source 1DOI PubMed

Cytokine engineering is presented as a promising strategy to overcome major barriers limiting CAR-T efficacy in solid tumors.

Claim 2strategy scopesupports2025Source 1DOI PubMed

External cell-based cytokine factories and immune-cytokines illustrate the versatility of localized cytokine delivery strategies beyond direct CAR-T engineering.

Claim 3therapeutic potentialsupports2025Source 1DOI PubMed

Cytokine-engineering strategies have potential to improve therapeutic outcomes in hematologic malignancies and a broad range of solid tumors.

Claim 4translation limitationsupports2025Source 1DOI PubMed

Cytokine-engineering strategies in CAR-T therapy remain in early clinical application because of safety and clinical translation limitations, including uncontrolled cytokine activation risk and manufacturing complexity.